Hims & Hers Health Key Executives
This section highlights Hims & Hers Health's key executives, including their titles and compensation details.
Find Contacts at Hims & Hers Health
( total contacts)
Hims & Hers Health Earnings
This section highlights Hims & Hers Health's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q1 | 2025 | 2025-05-05 | $0.12 | $0.20 |
| Read Transcript | Q4 | 2024 | 2025-02-24 | $0.09 | $0.11 |
| Read Transcript | Q3 | 2024 | 2024-11-04 | $0.06 | $0.06 |
| Read Transcript | Q2 | 2024 | 2024-08-05 | $0.04 | $0.06 |
| Read Transcript | Q1 | 2024 | 2024-05-06 | $0.01 | $0.05 |
| Read Transcript | Q4 | 2023 | 2024-02-26 | $0.00 | $0.01 |
| Read Transcript | Q3 | 2023 | 2023-11-06 | $-0.03 | $-0.04 |
| Read Transcript | Q2 | 2023 | 2023-08-07 | $-0.06 | $-0.03 |
| Read Transcript | Q1 | 2023 | 2023-05-08 | $-0.06 | $-0.05 |
Earnings Reports
Dive into Hims & Hers Health's earnings with our AI-powered insights.
Financial Statements
Access annual & quarterly financial statements for Hims & Hers Health, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $1.48B | $872.00M | $526.92M | $271.88M | $148.76M |
| Cost of Revenue | $303.38M | $157.05M | $118.19M | $67.38M | $39.31M |
| Gross Profit | $1.17B | $714.95M | $408.72M | $204.49M | $109.45M |
| Gross Profit Ratio | 79.45% | 81.99% | 77.57% | 75.22% | 73.58% |
| Research and Development Expenses | $78.82M | $48.23M | $29.24M | $22.38M | $11.24M |
| General and Administrative Expenses | $167.77M | $129.88M | $98.19M | $183.63M | $65.61M |
| Selling and Marketing Expenses | $678.84M | $446.44M | $272.59M | $135.90M | $58.99M |
| Selling General and Administrative Expenses | $846.61M | $692.73M | $370.78M | $319.54M | $124.59M |
| Other Expenses | $185.80M | $3.44M | $77.40M | $445.00K | $-11.24M |
| Operating Expenses | $1.11B | $744.40M | $477.42M | $319.54M | $124.59M |
| Cost and Expenses | $1.23B | $901.45M | $595.61M | $386.92M | $163.90M |
| Interest Income | $- | $- | $2.61M | $390.00K | $438.00K |
| Interest Expense | $- | $- | $- | $- | $10.00K |
| Depreciation and Amortization | $17.09M | $9.52M | $7.47M | $4.08M | $1.06M |
| EBITDA | $78.99M | $-19.94M | $-61.22M | $-110.97M | $-14.09M |
| EBITDA Ratio | 5.35% | -2.29% | -11.62% | -40.81% | -9.47% |
| Operating Income | $61.90M | $-29.45M | $-68.70M | $-115.04M | $-15.14M |
| Operating Income Ratio | 4.19% | -3.38% | -13.04% | -42.31% | -10.18% |
| Total Other Income Expenses Net | $9.81M | $7.88M | $2.99M | $4.25M | $-2.84M |
| Income Before Tax | $71.71M | $-21.57M | $-65.71M | $-110.80M | $-17.99M |
| Income Before Tax Ratio | 4.86% | -2.47% | -12.47% | -40.75% | -12.09% |
| Income Tax Expense | $-54.33M | $1.98M | $-31.00K | $-3.14M | $127.00K |
| Net Income | $126.04M | $-23.55M | $-65.68M | $-107.66M | $-18.11M |
| Net Income Ratio | 8.54% | -2.70% | -12.46% | -39.60% | -12.18% |
| EPS | $0.58 | $-0.11 | $-0.32 | $-0.58 | $-0.51 |
| EPS Diluted | $0.53 | $-0.11 | $-0.32 | $-0.58 | $-0.51 |
| Weighted Average Shares Outstanding | 215.94M | 209.34M | 204.52M | 186.78M | 35.35M |
| Weighted Average Shares Outstanding Diluted | 236.81M | 209.34M | 204.52M | 186.78M | 35.35M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | March 31, 2025 | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $586.01M | $481.14M | $401.56M | $315.65M | $278.17M | $246.62M | $226.70M | $207.91M | $190.77M | $167.20M | $144.84M | $113.56M | $101.31M | $84.70M | $74.17M | $60.69M | $52.31M | $41.47M | $41.32M | $35.90M |
| Cost of Revenue | $155.32M | $111.60M | $83.67M | $100.49M | $49.08M | $45.22M | $39.39M | $37.75M | $37.34M | $34.87M | $30.38M | $26.39M | $26.56M | $22.60M | $19.30M | $13.41M | $12.07M | $9.57M | $10.05M | $10.24M |
| Gross Profit | $430.69M | $369.54M | $317.89M | $215.16M | $229.09M | $201.40M | $187.31M | $170.16M | $153.43M | $132.34M | $114.45M | $87.18M | $74.76M | $62.10M | $54.87M | $47.28M | $40.25M | $31.89M | $31.28M | $25.66M |
| Gross Profit Ratio | 73.50% | 76.81% | 79.16% | 68.16% | 82.36% | 81.66% | 82.62% | 81.84% | 80.42% | 79.15% | 79.02% | 76.76% | 73.79% | 73.32% | 73.98% | 77.90% | 76.93% | 76.91% | 75.69% | 71.47% |
| Research and Development Expenses | $29.91M | $23.75M | $21.09M | $18.65M | $15.32M | $13.40M | $12.27M | $11.80M | $10.75M | $8.31M | $7.98M | $6.86M | $6.09M | $5.57M | $6.24M | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $48.61M | $48.03M | $44.62M | $40.55M | $34.57M | $32.32M | $35.91M | $31.14M | $30.51M | $27.57M | $48.00M | $46.88M | $43.58M | $40.96M | $44.24M | $36.74M | $61.70M | $17.20M | $19.50M | $14.84M |
| Selling and Marketing Expenses | $231.24M | $221.09M | $182.28M | $144.92M | $130.55M | $125.89M | $116.08M | $107.22M | $97.25M | $85.54M | $78.46M | $60.49M | $48.09M | $42.71M | $38.29M | $27.94M | $26.96M | $19.31M | $15.10M | $11.80M |
| Selling General and Administrative Expenses | $279.85M | $269.74M | $226.90M | $184.85M | $165.12M | $210.12M | $151.98M | $138.36M | $127.76M | $113.11M | $126.46M | $107.37M | $91.67M | $83.66M | $82.53M | $64.68M | $88.66M | $36.52M | $34.60M | $26.64M |
| Other Expenses | $- | $57.45M | $- | $2.39M | $2.50M | $2.60M | $1.64M | $2.07M | $26.18M | $22.52M | $677.00K | $402.00K | $320.00K | $125.00K | $219.00K | $325.00K | $-2.90M | $-579.00K | $8.00K | $56.00K |
| Operating Expenses | $309.76M | $350.94M | $295.51M | $203.50M | $219.19M | $210.12M | $195.86M | $179.39M | $164.69M | $143.94M | $134.44M | $107.37M | $91.67M | $83.66M | $82.53M | $64.68M | $88.66M | $36.52M | $34.60M | $26.64M |
| Cost and Expenses | $465.08M | $363.64M | $378.32M | $303.99M | $268.27M | $255.34M | $235.25M | $217.15M | $202.03M | $178.81M | $164.82M | $133.75M | $118.23M | $106.26M | $101.83M | $78.10M | $100.72M | $46.09M | $44.65M | $36.88M |
| Interest Income | $- | $- | $- | $- | $- | $- | $2.34M | $2.17M | $- | $1.47M | $607.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $- | $6.06M | $4.38M | $3.64M | $3.00M | $2.66M | $2.36M | $2.38M | $2.12M | $2.01M | $1.90M | $1.82M | $1.74M | $1.63M | $1.55M | $505.00K | $394.00K | $365.00K | $300.00K | $212.00K |
| EBITDA | $57.90M | $24.66M | $26.76M | $14.67M | $12.90M | $2.26M | $-6.19M | $-6.86M | $-8.72M | $-11.61M | $-16.95M | $-18.37M | $-15.18M | $-29.62M | $-26.11M | $-17.41M | $-48.02M | $-4.26M | $-3.01M | $-767.00K |
| EBITDA Ratio | 9.88% | 5.12% | 6.66% | 4.65% | 4.64% | 0.92% | -2.73% | -3.30% | -4.57% | -6.94% | -11.71% | -16.18% | -14.98% | -34.97% | -35.21% | -28.68% | -91.78% | -10.28% | -7.29% | -2.14% |
| Operating Income | $57.90M | $18.60M | $22.37M | $11.66M | $9.90M | $-8.72M | $-8.55M | $-9.24M | $-11.26M | $-11.61M | $-19.98M | $-20.19M | $-16.92M | $-21.57M | $-27.66M | $-17.41M | $-48.41M | $-4.63M | $-3.32M | $-979.00K |
| Operating Income Ratio | 9.88% | 3.86% | 5.57% | 3.69% | 3.56% | -3.54% | -3.77% | -4.44% | -5.90% | -6.94% | -13.80% | -17.78% | -16.70% | -25.46% | -37.29% | -28.68% | -92.54% | -11.16% | -8.04% | -2.73% |
| Total Other Income Expenses Net | $2.60M | $3.69M | $1.22M | $2.39M | $2.50M | $2.60M | $1.64M | $2.07M | $1.58M | $577.00K | $1.13M | $523.00K | $761.00K | $-9.68M | $8.55M | $8.29M | $-2.90M | $-579.00K | $-2.52M | $35.00K |
| Income Before Tax | $60.49M | $22.29M | $23.59M | $13.42M | $12.40M | $2.20M | $-6.92M | $-7.17M | $-9.68M | $-11.03M | $-18.86M | $-19.67M | $-16.16M | $-31.25M | $-19.11M | $-9.12M | $-51.31M | $-5.21M | $-5.84M | $-944.00K |
| Income Before Tax Ratio | 10.32% | 4.63% | 5.88% | 4.25% | 4.46% | 0.89% | -3.05% | -3.45% | -5.07% | -6.60% | -13.02% | -17.32% | -15.95% | -36.89% | -25.77% | -15.03% | -98.09% | -12.55% | -14.13% | -2.63% |
| Income Tax Expense | $-11.01M | $-3.73M | $-51.99M | $127.00K | $1.27M | $951.00K | $651.00K | $-13.00K | $386.00K | $-121.00K | $-16.00K | $12.00K | $94.00K | $-87.00K | $-3.17M | $34.00K | $90.00K | $24.00K | $31.00K | $37.00K |
| Net Income | $49.48M | $26.02M | $75.59M | $13.30M | $11.13M | $1.25M | $-7.57M | $-7.16M | $-10.07M | $-10.91M | $-18.84M | $-19.68M | $-16.25M | $-31.16M | $-15.94M | $-9.15M | $-51.40M | $-5.23M | $-5.87M | $-981.00K |
| Net Income Ratio | 8.44% | 5.41% | 18.82% | 4.21% | 4.00% | 0.50% | -3.34% | -3.44% | -5.28% | -6.52% | -13.01% | -17.33% | -16.04% | -36.79% | -21.49% | -15.08% | -98.26% | -12.61% | -14.21% | -2.73% |
| EPS | $0.22 | $0.12 | $0.35 | $0.06 | $0.05 | $0.01 | $-0.04 | $-0.03 | $-0.05 | $-0.05 | $-0.09 | $-0.10 | $-0.08 | $-0.15 | $-0.08 | $-0.05 | $-0.34 | $-0.07 | $-0.16 | $-0.03 |
| EPS Diluted | $0.20 | $0.11 | $0.32 | $0.06 | $0.05 | $0.01 | $-0.04 | $-0.03 | $-0.05 | $-0.05 | $-0.09 | $-0.10 | $-0.08 | $-0.15 | $-0.08 | $-0.05 | $-0.34 | $-0.07 | $-0.16 | $-0.03 |
| Weighted Average Shares Outstanding | 221.99M | 219.03M | 216.62M | 214.62M | 213.45M | 211.58M | 210.13M | 208.42M | 207.14M | 206.14M | 205.23M | 203.33M | 202.70M | 201.36M | 200.04M | 191.92M | 153.08M | 79.31M | 35.61M | 35.33M |
| Weighted Average Shares Outstanding Diluted | 246.61M | 240.73M | 235.07M | 234.79M | 229.36M | 221.85M | 210.13M | 208.42M | 207.14M | 206.14M | 205.23M | 203.95M | 202.70M | 201.36M | 200.04M | 191.92M | 153.08M | 79.31M | 35.61M | 35.33M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $220.58M | $96.66M | $46.77M | $71.78M | $27.34M |
| Short Term Investments | $79.67M | $124.32M | $132.85M | $175.49M | $72.86M |
| Cash and Short Term Investments | $300.25M | $220.98M | $179.62M | $247.27M | $100.21M |
| Net Receivables | $- | $5.71M | $3.23M | $3.58M | $750.00K |
| Inventory | $64.43M | $22.46M | $21.56M | $13.56M | $3.54M |
| Other Current Assets | $8.90M | $15.90M | $12.18M | $5.50M | $8.58M |
| Total Current Assets | $395.83M | $265.05M | $216.59M | $269.90M | $113.08M |
| Property Plant Equipment Net | $92.96M | $45.73M | $4.94M | $5.11M | $1.70M |
| Goodwill | $112.73M | $110.88M | $110.88M | $110.88M | $- |
| Intangible Assets | $43.41M | $18.57M | $21.84M | $25.89M | $59.00K |
| Goodwill and Intangible Assets | $156.14M | $129.46M | $132.72M | $136.77M | $59.00K |
| Long Term Investments | $- | $- | $856.00K | $856.00K | $204.53M |
| Tax Assets | $61.60M | $- | $-856.00K | $-856.00K | $-1.70M |
| Other Non-Current Assets | $1.00M | $947.00K | $12.09M | $8.80M | $-198.97M |
| Total Non-Current Assets | $311.71M | $176.13M | $149.75M | $150.68M | $5.61M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $707.54M | $441.19M | $366.34M | $420.58M | $118.70M |
| Account Payables | $91.18M | $43.07M | $32.36M | $19.64M | $8.07M |
| Short Term Debt | $1.89M | $2.56M | $3.32M | $2.73M | $- |
| Tax Payables | $- | $2.01M | $963.00K | $954.00K | $651.00K |
| Deferred Revenue | $75.28M | $7.73M | $1.47M | $3.19M | $1.27M |
| Other Current Liabilities | $53.01M | $33.09M | $8.17M | $52.71M | $5.24M |
| Total Current Liabilities | $221.37M | $88.47M | $47.94M | $79.22M | $15.23M |
| Long Term Debt | $- | $8.67M | $3.65M | $4.12M | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $22.00K | $3.01M | $2.63M | $250.34M |
| Total Non-Current Liabilities | $9.46M | $8.69M | $6.66M | $6.75M | $250.34M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $230.82M | $97.16M | $54.60M | $85.97M | $265.57M |
| Preferred Stock | $- | $- | $- | $- | $249.96M |
| Common Stock | $22.00K | $21.00K | $21.00K | $20.00K | $5.00K |
| Retained Earnings | $-242.14M | $-368.18M | $-344.63M | $-278.95M | $-171.29M |
| Accumulated Other Comprehensive Income Loss | $-324.00K | $-124.00K | $-277.00K | $-137.00K | $-11.00K |
| Other Total Stockholders Equity | $719.15M | $712.31M | $656.63M | $613.69M | $-225.54M |
| Total Stockholders Equity | $476.72M | $344.03M | $311.74M | $334.62M | $-146.87M |
| Total Equity | $476.72M | $344.03M | $311.74M | $334.62M | $-146.87M |
| Total Liabilities and Stockholders Equity | $707.54M | $441.19M | $366.34M | $420.58M | $118.70M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $707.54M | $441.19M | $366.34M | $420.58M | $118.70M |
| Total Investments | $79.67M | $124.32M | $132.85M | $175.49M | $277.39M |
| Total Debt | $11.35M | $9.95M | $5.31M | $5.48M | $- |
| Net Debt | $-209.24M | $-86.72M | $-41.47M | $-66.30M | $-27.34M |
Balance Sheet Charts
| Breakdown | March 31, 2025 | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $273.74M | $220.58M | $165.52M | $129.29M | $105.24M | $96.66M | $58.00M | $65.42M | $48.74M | $46.77M | $57.96M | $55.03M | $48.28M | $71.78M | $64.77M | $107.14M | $88.17M | $27.34M | $36.40M | $45.65M |
| Short Term Investments | $48.94M | $79.67M | $88.55M | $98.00M | $98.36M | $124.32M | $154.50M | $127.72M | $135.65M | $132.85M | $140.43M | $139.94M | $154.77M | $175.49M | $187.65M | $210.18M | $235.10M | $72.86M | $59.15M | $42.75M |
| Cash and Short Term Investments | $322.67M | $300.25M | $254.07M | $227.29M | $203.59M | $220.98M | $212.50M | $193.14M | $184.39M | $179.62M | $198.39M | $194.98M | $203.05M | $247.27M | $252.43M | $317.32M | $323.27M | $100.21M | $95.55M | $88.40M |
| Net Receivables | $- | $- | $4.57M | $5.55M | $6.41M | $5.71M | $4.23M | $3.90M | $4.47M | $3.23M | $3.81M | $4.94M | $5.46M | $3.58M | $1.32M | $1.25M | $- | $750.00K | $1.27M | $2.00M |
| Inventory | $76.10M | $64.43M | $49.11M | $40.59M | $29.83M | $22.46M | $21.99M | $21.42M | $20.70M | $21.56M | $22.35M | $19.67M | $12.14M | $13.56M | $10.86M | $6.59M | $4.52M | $3.54M | $4.95M | $6.22M |
| Other Current Assets | $48.20M | $8.90M | $18.62M | $17.49M | $21.91M | $15.90M | $11.50M | $16.19M | $15.96M | $12.18M | $8.91M | $10.90M | $11.29M | $5.50M | $9.63M | $11.18M | $12.41M | $8.58M | $5.37M | $3.81M |
| Total Current Assets | $446.96M | $395.83M | $326.38M | $290.92M | $261.73M | $265.05M | $250.22M | $234.65M | $225.53M | $216.59M | $233.46M | $230.49M | $231.95M | $269.90M | $274.23M | $336.34M | $340.20M | $113.08M | $107.13M | $100.42M |
| Property Plant Equipment Net | $217.91M | $92.96M | $63.03M | $60.57M | $56.63M | $45.73M | $32.54M | $4.74M | $4.55M | $4.94M | $5.32M | $4.46M | $4.79M | $5.11M | $- | $- | $- | $1.70M | $- | $- |
| Goodwill | $117.75M | $112.73M | $112.73M | $110.88M | $110.88M | $110.88M | $110.88M | $110.88M | $110.88M | $110.88M | $110.88M | $110.88M | $110.88M | $110.88M | $110.88M | $2.74M | $- | $- | $- | $- |
| Intangible Assets | $43.43M | $43.41M | $44.82M | $17.13M | $17.86M | $18.57M | $19.30M | $19.96M | $20.91M | $21.84M | $22.09M | $23.81M | $24.85M | $25.89M | $26.93M | $- | $- | $59.00K | $- | $- |
| Goodwill and Intangible Assets | $161.18M | $156.14M | $157.55M | $128.01M | $128.74M | $129.46M | $130.18M | $130.84M | $131.79M | $132.72M | $132.97M | $134.69M | $135.73M | $136.77M | $137.81M | $2.74M | $- | $59.00K | $- | $- |
| Long Term Investments | $- | $- | $- | $856.00K | $856.00K | $856.00K | $856.00K | $856.00K | $856.00K | $856.00K | $856.00K | $856.00K | $856.00K | $856.00K | $856.00K | $856.00K | $856.00K | $204.53M | $7.23M | $204.73M |
| Tax Assets | $62.49M | $61.60M | $54.32M | $- | $-856.00K | $- | $-856.00K | $-856.00K | $-856.00K | $-856.00K | $-856.00K | $-856.00K | $-856.00K | $-856.00K | $- | $- | $- | $-1.70M | $- | $- |
| Other Non-Current Assets | $3.17M | $1.00M | $994.00K | $138.00K | $994.00K | $91.00K | $928.00K | $19.66M | $14.44M | $12.09M | $11.08M | $10.33M | $9.58M | $8.80M | $7.17M | $7.76M | $4.85M | $-198.97M | $4.83M | $-200.68M |
| Total Non-Current Assets | $444.75M | $311.71M | $275.89M | $189.58M | $186.37M | $176.13M | $163.65M | $155.24M | $150.78M | $149.75M | $149.37M | $149.48M | $150.09M | $150.68M | $145.84M | $11.36M | $5.70M | $5.61M | $12.06M | $4.05M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $891.71M | $707.54M | $602.26M | $480.50M | $448.11M | $441.19M | $413.87M | $389.88M | $376.31M | $366.34M | $382.83M | $379.96M | $382.04M | $420.58M | $420.07M | $347.70M | $345.90M | $118.70M | $119.19M | $104.47M |
| Account Payables | $108.92M | $91.18M | $75.44M | $57.10M | $43.92M | $43.07M | $42.00M | $38.27M | $37.61M | $32.36M | $32.97M | $27.09M | $23.91M | $19.64M | $16.09M | $15.56M | $13.23M | $8.07M | $6.71M | $21.66K |
| Short Term Debt | $3.74M | $1.89M | $3.59M | $3.27M | $1.54M | $2.56M | $3.86M | $3.68M | $1.69M | $1.66M | $3.21M | $2.82M | $2.78M | $1.36M | $- | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $3.39M | $1.16M | $3.29M | $2.01M | $1.32M | $605.00K | $1.09M | $963.00K | $798.00K | $673.00K | $1.01M | $954.00K | $755.00K | $641.00K | $- | $651.00K | $635.00K | $- |
| Deferred Revenue | $110.77M | $75.28M | $32.18M | $20.99M | $13.73M | $7.73M | $4.39M | $2.06M | $2.87M | $1.47M | $2.12M | $2.34M | $1.15M | $3.19M | $1.99M | $1.02M | $624.00K | $1.27M | $688.00K | $- |
| Other Current Liabilities | $56.94M | $53.01M | $38.04M | $46.06M | $30.84M | $33.09M | $30.97M | $21.94M | $13.03M | $11.48M | $27.71M | $22.70M | $19.67M | $54.07M | $33.66M | $10.12M | $5.82M | $6.51M | $9.64M | $15.14M |
| Total Current Liabilities | $280.36M | $221.37M | $152.65M | $108.67M | $93.32M | $88.47M | $82.55M | $66.55M | $56.28M | $47.94M | $66.82M | $55.62M | $48.50M | $79.22M | $52.50M | $27.34M | $19.68M | $15.23M | $16.98M | $15.16M |
| Long Term Debt | $59.65M | $- | $9.56M | $9.84M | $10.28M | $8.67M | $2.75M | $3.25M | $3.22M | $3.65M | $4.08M | $3.40M | $3.76M | $4.12M | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $2.44M | $- | $- | $22.00K | $21.00K | $22.00K | $5.00K | $14.00K | $4.06M | $3.01M | $988.00K | $1.88M | $2.06M | $2.63M | $12.42M | $27.30M | $33.75M | $250.34M | $245.55M | $7.19M |
| Total Non-Current Liabilities | $62.09M | $9.46M | $9.56M | $9.86M | $10.30M | $8.69M | $2.76M | $3.27M | $7.28M | $6.66M | $5.06M | $5.28M | $5.82M | $6.75M | $12.42M | $27.30M | $33.75M | $250.34M | $245.55M | $7.19M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-7.19M |
| Total Liabilities | $342.45M | $230.82M | $162.21M | $118.53M | $103.62M | $97.16M | $85.30M | $69.81M | $63.56M | $54.60M | $71.88M | $60.91M | $54.32M | $85.97M | $64.92M | $54.65M | $53.43M | $265.57M | $262.53M | $15.16M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $249.96M | $245.17M | $228.13M |
| Common Stock | $22.00K | $22.00K | $22.00K | $22.00K | $21.00K | $21.00K | $21.00K | $21.00K | $21.00K | $21.00K | $21.00K | $21.00K | $21.00K | $20.00K | $20.00K | $19.00K | $18.00K | $5.00K | $190.58M | $192.84M |
| Retained Earnings | $-192.65M | $-242.14M | $-268.16M | $-343.75M | $-357.05M | $-368.18M | $-369.42M | $-361.85M | $-354.70M | $-344.63M | $-333.72M | $-314.88M | $-295.20M | $-278.95M | $-247.79M | $-231.85M | $-222.70M | $-171.29M | $-166.06M | $-160.19M |
| Accumulated Other Comprehensive Income Loss | $-164.00K | $-324.00K | $229.00K | $-168.00K | $-162.00K | $-124.00K | $-133.00K | $-258.00K | $-111.00K | $-277.00K | $-462.00K | $-468.00K | $-323.00K | $-137.00K | $-52.00K | $-40.00K | $-72.00K | $-11.00K | $-10.00K | $-16.00K |
| Other Total Stockholders Equity | $742.05M | $719.15M | $707.96M | $705.86M | $701.67M | $712.31M | $698.09M | $682.16M | $667.53M | $656.63M | $645.11M | $634.39M | $623.22M | $613.69M | $602.98M | $524.92M | $515.22M | $176.30M | $-19.51M | $165.21M |
| Total Stockholders Equity | $549.26M | $476.72M | $440.05M | $361.97M | $344.48M | $344.03M | $328.56M | $320.07M | $312.75M | $311.74M | $310.95M | $319.06M | $327.71M | $334.62M | $355.15M | $293.05M | $292.47M | $-146.87M | $-143.34M | $89.18M |
| Total Equity | $549.26M | $476.72M | $440.05M | $361.97M | $344.48M | $344.03M | $328.56M | $320.07M | $312.75M | $311.74M | $310.95M | $319.06M | $327.71M | $334.62M | $355.15M | $293.05M | $292.47M | $-146.87M | $-143.34M | $89.18M |
| Total Liabilities and Stockholders Equity | $891.71M | $707.54M | $602.26M | $480.50M | $448.11M | $441.19M | $413.87M | $389.88M | $376.31M | $366.34M | $382.83M | $379.96M | $382.04M | $420.58M | $420.07M | $347.70M | $345.90M | $118.70M | $119.19M | $104.34M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $891.71M | $707.54M | $602.26M | $480.50M | $448.11M | $441.19M | $413.87M | $389.88M | $376.31M | $366.34M | $382.83M | $379.96M | $382.04M | $420.58M | $420.07M | $347.70M | $345.90M | $118.70M | $119.19M | $104.34M |
| Total Investments | $48.94M | $79.67M | $88.55M | $98.85M | $98.36M | $125.17M | $154.50M | $127.72M | $135.65M | $132.85M | $140.43M | $139.94M | $154.77M | $175.49M | $187.65M | $210.18M | $235.10M | $277.39M | $66.37M | $42.75M |
| Total Debt | $63.38M | $11.35M | $11.36M | $11.47M | $11.82M | $9.95M | $4.68M | $5.09M | $4.90M | $5.31M | $5.68M | $4.81M | $5.15M | $5.48M | $- | $- | $- | $- | $- | $- |
| Net Debt | $-210.35M | $-209.24M | $-154.16M | $-117.82M | $-93.41M | $-86.72M | $-53.31M | $-60.33M | $-43.84M | $-41.47M | $-52.28M | $-50.22M | $-43.13M | $-66.30M | $-64.77M | $-107.14M | $-88.17M | $-27.34M | $-36.40M | $-45.65M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $126.04M | $-23.55M | $-65.68M | $-107.66M | $-18.11M |
| Depreciation and Amortization | $17.09M | $9.52M | $7.47M | $4.08M | $1.06M |
| Deferred Income Tax | $-61.65M | $-13.00K | $-594.00K | $-3.39M | $- |
| Stock Based Compensation | $92.32M | $66.08M | $42.82M | $67.21M | $5.83M |
| Change in Working Capital | $78.62M | $20.82M | $-14.20M | $3.46M | $4.19M |
| Accounts Receivables | $- | $- | $- | $1.82M | $1.79M |
| Inventory | $-41.61M | $-902.00K | $-8.00M | $-9.63M | $674.00K |
| Accounts Payables | $43.71M | $7.32M | $12.72M | $9.85M | $826.00K |
| Other Working Capital | $76.53M | $14.40M | $-18.91M | $1.41M | $900.00K |
| Other Non Cash Items | $-1.34M | $626.00K | $3.65M | $1.89M | $4.56M |
| Net Cash Provided by Operating Activities | $251.08M | $73.48M | $-26.53M | $-34.41M | $-2.48M |
| Investments in Property Plant and Equipment | $-41.66M | $-17.22M | $-7.25M | $-5.01M | $-4.23M |
| Acquisitions Net | $-15.40M | $- | $-459.00K | $-46.47M | $2.50M |
| Purchases of Investments | $-160.56M | $-157.24M | $-187.70M | $-266.63M | $-95.01M |
| Sales Maturities of Investments | $209.66M | $171.62M | $230.10M | $161.84M | $59.54M |
| Other Investing Activities | $-11.10M | $-9.27M | $-459.00K | $-108.97M | $-2.50M |
| Net Cash Used for Investing Activities | $-19.05M | $-12.11M | $34.70M | $-156.27M | $-39.70M |
| Debt Repayment | $- | $- | $- | $1.19M | $-1.51M |
| Common Stock Issued | $- | $- | $2.25M | $272.69M | $49.26M |
| Common Stock Repurchased | $-83.04M | $-2.00M | $-3.90M | $-22.03M | $-49.26M |
| Dividends Paid | $- | $- | $- | $- | $-1.74M |
| Other Financing Activities | $-24.81M | $-9.48M | $-33.13M | $-16.81M | $49.26M |
| Net Cash Used Provided by Financing Activities | $-107.84M | $-11.47M | $-33.13M | $235.04M | $47.74M |
| Effect of Forex Changes on Cash | $-270.00K | $-11.00K | $-53.00K | $-73.00K | $-9.00K |
| Net Change in Cash | $123.92M | $49.89M | $-25.01M | $44.29M | $5.55M |
| Cash at End of Period | $221.44M | $97.52M | $47.63M | $72.64M | $28.35M |
| Cash at Beginning of Period | $97.52M | $47.63M | $72.64M | $28.35M | $22.80M |
| Operating Cash Flow | $251.08M | $73.48M | $-26.53M | $-34.41M | $-2.48M |
| Capital Expenditure | $-41.66M | $-26.49M | $-7.25M | $-5.01M | $-4.23M |
| Free Cash Flow | $209.43M | $46.99M | $-33.78M | $-39.42M | $-6.71M |
Cash Flow Charts
| Breakdown | March 31, 2025 | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $49.48M | $26.02M | $75.59M | $13.30M | $11.13M | $1.25M | $-7.57M | $-7.16M | $-10.07M | $-10.91M | $-18.84M | $-19.68M | $-16.25M | $-31.16M | $-15.94M | $-9.15M | $-51.40M | $-5.23M | $-5.87M | $-981.00K |
| Depreciation and Amortization | $8.28M | $6.06M | $4.38M | $3.64M | $3.00M | $2.66M | $2.36M | $2.38M | $2.12M | $2.01M | $1.90M | $1.82M | $1.74M | $1.63M | $1.55M | $505.00K | $394.00K | $365.00K | $300.00K | $212.00K |
| Deferred Income Tax | $-890.00K | $-7.31M | $- | $- | $- | $17.00K | $-10.00K | $-69.00K | $49.00K | $-214.00K | $-122.00K | $-146.00K | $-112.00K | $-210.00K | $-1.45M | $- | $154.00K | $-2.15M | $2.48M | $- |
| Stock Based Compensation | $24.86M | $24.35M | $24.90M | $24.04M | $19.03M | $17.79M | $17.28M | $16.84M | $14.17M | $12.35M | $10.98M | $10.63M | $8.86M | $11.95M | $11.87M | $9.16M | $34.23M | $1.09M | $1.41M | $1.93M |
| Change in Working Capital | $- | $37.58M | $35.22M | $13.13M | $-7.30M | $2.79M | $12.35M | $5.17M | $2.44M | $-11.54M | $11.12M | $677.00K | $-14.45M | $2.08M | $-3.57M | $7.54M | $-2.60M | $3.54M | $2.80M | $-1.41M |
| Accounts Receivables | $- | $- | $- | $- | $- | $-16.84M | $11.63M | $5.21M | $- | $- | $- | $- | $- | $39.00K | $886.00K | $6.98M | $-6.09M | $204.00K | $1.31M | $189.00K |
| Inventory | $-11.67M | $-15.32M | $-8.17M | $-10.76M | $-7.36M | $-472.00K | $-575.00K | $-720.00K | $865.00K | $785.00K | $-2.67M | $-7.53M | $1.42M | $-2.70M | $-3.88M | $-2.07M | $-980.00K | $1.41M | $1.27M | $-4.00K |
| Accounts Payables | $14.47M | $8.66M | $18.90M | $12.55M | $3.60M | $2.92M | $-1.04M | $1.48M | $3.96M | $-609.00K | $5.88M | $3.19M | $4.27M | $3.55M | $-1.05M | $2.24M | $5.12M | $1.72M | $164.00K | $-1.74M |
| Other Working Capital | $- | $44.24M | $24.49M | $11.33M | $-3.54M | $342.00K | $2.33M | $-808.00K | $-2.38M | $-11.72M | $7.92M | $5.02M | $-20.13M | $1.20M | $470.00K | $392.00K | $-645.00K | $205.00K | $50.00K | $138.00K |
| Other Non Cash Items | $27.36M | $-322.00K | $-54.82M | $-514.00K | $-20.00K | $-588.00K | $779.00K | $-337.00K | $772.00K | $1.59M | $945.00K | $301.00K | $813.00K | $12.60M | $-8.42M | $-7.46M | $3.28M | $2.12M | $2.02M | $101.00K |
| Net Cash Provided by Operating Activities | $109.09M | $86.39M | $85.27M | $53.59M | $25.84M | $23.92M | $25.19M | $16.83M | $9.48M | $-6.72M | $5.99M | $-6.39M | $-19.40M | $-3.10M | $-15.96M | $601.00K | $-15.95M | $-269.00K | $3.14M | $-155.00K |
| Investments in Property Plant and Equipment | $-55.33M | $-24.52M | $-3.34M | $-3.21M | $-10.58M | $-11.20M | $-5.92M | $-6.86M | $-2.51M | $-2.61M | $-1.96M | $-1.38M | $-1.30M | $-1.49M | $-1.57M | $-1.15M | $-803.00K | $-1.29M | $-1.09M | $-1.13M |
| Acquisitions Net | $-5.10M | $- | $- | $- | $- | $-29.33M | $2.64M | $2.19M | $1.88M | $1.21M | $1.54M | $-459.00K | $1.20M | $-748.00K | $-45.72M | $1.09M | $740.00K | $845.00K | $601.00K | $598.00K |
| Purchases of Investments | $- | $-9.97M | $-53.06M | $-26.84M | $-70.70M | $-20.82M | $-71.04M | $-24.69M | $-40.69M | $-50.88M | $-47.67M | $-4.26M | $-84.88M | $-47.27M | $-31.84M | $-15.50M | $-172.02M | $-10.99M | $-35.11M | $-31.27M |
| Sales Maturities of Investments | $31.34M | $19.65M | $63.92M | $28.39M | $97.70M | $52.72M | $45.90M | $33.93M | $39.08M | $59.50M | $47.05M | $18.92M | $104.63M | $59.00M | $53.20M | $40.14M | $9.50M | $4.20M | $11.45M | $18.29M |
| Other Investing Activities | $-3.71M | $-2.37M | $-17.94M | $-2.81M | $-3.38M | $29.33M | $-2.64M | $-2.19M | $-1.88M | $-1.21M | $-1.54M | $-459.00K | $-1.20M | $748.00K | $19.95M | $-1.84M | $-740.00K | $-845.00K | $-601.00K | $-598.00K |
| Net Cash Used for Investing Activities | $-32.80M | $-17.21M | $-10.41M | $-4.47M | $13.04M | $20.70M | $-31.06M | $2.37M | $-4.11M | $6.00M | $-2.58M | $12.82M | $18.45M | $10.24M | $-25.92M | $22.74M | $-163.32M | $-8.08M | $-24.75M | $-14.10M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.19M | $- | $- | $1.19M | $- | $- | $-357.00K |
| Common Stock Issued | $12.76M | $- | $- | $- | $- | $2.03M | $1.13M | $1.21M | $245.00K | $714.00K | $687.00K | $1.13M | $891.00K | $- | $292.00K | $118.00K | $272.69M | $- | $- | $- |
| Common Stock Repurchased | $- | $-5.00M | $-30.04M | $-19.93M | $-28.06M | $-2.00M | $-2.69M | $-3.75M | $-3.66M | $- | $-1.18M | $-779.00K | $-404.00K | $-764.00K | $-776.00K | $-4.46M | $-22.03M | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.74M | $- | $- |
| Other Financing Activities | $-23.02M | $-8.65M | $-8.78M | $-5.13M | $-2.24M | $-3.96M | $-1.56M | $-2.54M | $-3.41M | $-11.17M | $-494.00K | $353.00K | $-22.53M | $-507.00K | $-484.00K | $-4.34M | $-11.91M | $-734.00K | $12.37M | $6.10M |
| Net Cash Used Provided by Financing Activities | $-23.02M | $-13.65M | $-38.82M | $-25.07M | $-30.31M | $-5.90M | $-1.56M | $-2.54M | $-3.41M | $-10.46M | $-494.00K | $353.00K | $-22.53M | $-78.00K | $-484.00K | $-4.34M | $239.94M | $-707.00K | $12.37M | $5.75M |
| Effect of Forex Changes on Cash | $- | $-461.00K | $190.00K | $-1.00K | $2.00K | $-48.00K | $8.00K | $14.00K | $15.00K | $-17.00K | $16.00K | $-29.00K | $-23.00K | $-47.00K | $-7.00K | $-21.00K | $2.00K | $2.00K | $1.00K | $-3.00K |
| Net Change in Cash | $53.52M | $55.07M | $36.22M | $24.06M | $8.57M | $38.67M | $-7.42M | $16.67M | $1.97M | $-11.19M | $2.93M | $6.75M | $-23.50M | $7.01M | $-42.37M | $18.98M | $60.67M | $-9.06M | $-9.25M | $-8.51M |
| Cash at End of Period | $274.96M | $221.44M | $166.37M | $130.15M | $106.09M | $96.66M | $58.85M | $66.27M | $49.60M | $47.63M | $58.82M | $55.89M | $49.14M | $72.64M | $65.63M | $108.00M | $89.03M | $28.35M | $37.41M | $46.65M |
| Cash at Beginning of Period | $221.44M | $166.37M | $130.15M | $106.09M | $97.52M | $58.00M | $66.27M | $49.60M | $47.63M | $58.82M | $55.89M | $49.14M | $72.64M | $65.63M | $108.00M | $89.03M | $28.35M | $37.41M | $46.65M | $55.16M |
| Operating Cash Flow | $109.09M | $86.39M | $85.27M | $53.59M | $25.84M | $23.92M | $25.19M | $16.83M | $9.48M | $-6.72M | $5.99M | $-6.39M | $-19.40M | $-3.10M | $-15.96M | $601.00K | $-15.95M | $-269.00K | $3.14M | $-155.00K |
| Capital Expenditure | $-55.33M | $-26.89M | $-5.88M | $-6.03M | $-13.96M | $-11.20M | $-5.92M | $-6.86M | $-2.51M | $-2.61M | $-1.96M | $-1.38M | $-1.30M | $-1.49M | $-1.57M | $-1.15M | $-803.00K | $-1.29M | $-1.09M | $-1.13M |
| Free Cash Flow | $53.76M | $59.50M | $79.39M | $47.57M | $11.88M | $12.72M | $19.27M | $9.96M | $6.97M | $-9.33M | $4.02M | $-7.77M | $-20.70M | $-4.59M | $-17.53M | $-551.00K | $-16.75M | $-1.56M | $2.04M | $-1.28M |
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.
$61.68
Stock Price
$13.29B
Market Cap
1.64K
Employees
San Francisco, CA
Location
Revenue (FY 2024)
$1.48B
69.3% YoY
Net Income (FY 2024)
$126.04M
635.3% YoY
EPS (FY 2024)
$0.53
581.8% YoY
Free Cash Flow (FY 2024)
$209.43M
345.7% YoY
Profitability
Gross Margin
79.5%
Net Margin
8.5%
ROE
26.4%
ROA
17.8%
Valuation
P/E Ratio
41.43
P/S Ratio
3.54
EV/EBITDA
63.45
Market Cap
$13.29B
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$251.08M
241.7% YoY
Free Cash Flow
$209.43M
345.7% YoY
Balance Sheet Summary
Total Assets
$707.54M
60.4% YoY
Total Debt
$11.35M
14.0% YoY
Shareholder Equity
$476.72M
34.3% YoY
Dividend Overview
No Dividend Data
Hims & Hers Health, Inc. doesn't currently pay dividends.
Hims & Hers Health Dividends
Explore Hims & Hers Health's dividend history, including dividend yield, payout ratio, and historical payments.
Hims & Hers Health News
Read the latest news about Hims & Hers Health, including recent articles, headlines, and updates.
Hims & Hers: Growth, Strategic Partnerships, And Operational Leverage (Upgrade)
Hims & Hers Health's rapid revenue and subscriber growth, plus improving cash generation, highlight strong business momentum and brand strength. Gross margins have declined due to lower-margin obesity products, but SG&A as a percentage of revenue is improving, supporting better operating leverage. The recent Novo Nordisk collaboration and capital raise position Hims for expansion, though reliance on GLP-1 drugs and competition are key risks.
Hims & Hers Health Stock: A Rare High-Growth Value Play In Plain Sight
Rarely I see high-growth, value plays in the market. I think Hims & Hers Health is such a rare case: a world-class, high-growth company still being valued as a risky startup. A DCF model based on 2030 guidance suggests a $64 fair value per share, with potential to far exceed that price due to management's conservative guidance. I think HIMS stock's fair value is above $84 per share, with potential to upwards of $300 per share in a bullish case scenario (2030 DCF model).
Hims & Hers: Still Undervalued For These 2 Reasons
Hims' operating leverage was outstanding at 5:1 over revenue growth. This is irrefutable proof of a scalable business. Hims' new TAMs should provide billions to the top line, hundreds of millions to the bottom, and dollars to EPS. Hims is likely a decade-plus ahead of competitors at this point with 'The Hims Trinity.'
Hims & Hers: Short-Lived Turbulence To Be Followed By New Phase Of Profitable Growth
Hims & Hers delivered impressive Q1 2025 results, with 111% y/y revenue growth and 38% y/y subscriber growth, driven by strong uptake of personalized GLP-1 offerings. Despite a projected Q2 revenue decline due to product transitions, management reaffirmed full-year 2025 revenue guidance of $2.3–2.4B and raised adj. EBITDA guidance to $295–335M. Long-term growth prospects remain strong, with a target of $6.5B+ revenue and $1.3B+ adj. EBITDA by 2030, driven by TAM penetration, new specialties, and AI integration.
Hims & Hers: Wegovy Deal Opens New Growth Chapter - Missed The Rally? Selling Puts Could Yield 30%
Hims & Hers Health rebounded from a 60% stock drop by partnering with Novo Nordisk, offering Wegovy at a competitive price, boosting accessibility and growth. Q1 earnings were exceptional with 111% YoY revenue growth and a 345% increase in net income, highlighting a sustainable and resilient business model. The company's personalized healthcare approach and new product launches, like low testosterone and menopause support, are driving subscriber growth and higher revenue per subscriber.
Massive Hims & Hers News: $1 Billion on AI and Acquisitions
Hims & Hers (NYSE: HIMS) stock has been on fire in 2025, and the company just got more great news after upsizing a $450 million convertible debt offering to up to $1 billion. The growth of Hims & Hers should move overseas, and artificial intelligence will play a bigger role in its future now.
Hims & Hers Health, Inc. Prices Upsized $870.0 Million Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced the pricing of its offering of $870,000,000 aggregate principal amount of 0.00% convertible senior notes due 2030 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced of.
Hims & Hers Stock's 100% Surge Is Squeezing Shorts And It Might Just Be Getting Started
If short sellers were hoping for a flop from Hims & Hers Health Inc. HIMS, they may want to check their risk management settings. The telehealth disruptor dropped first-quarter earnings after the bell on Monday, and instead of the crash shorts were counting on, the market got a bullish cocktail: strong guidance, solid revenue growth and a headline-making partnership with Novo Nordisk A/S NVO.
Hims & Hers: The Road To Blue Chip Status
Personalized subscribers grew 136% YoY, reflecting a fundamental shift towards precision medicine. Despite declining gross margins, HIMS achieved 13pp of operating leverage in Q1. This is by far HIMS' best quarter to date. The markets need to put some respect on Andrew Dudum and his world-class team.
Hims & Hers Soars Again--Explosive Growth Meets Lofty Expectations
Hims & Hers stock has surged due to impressive quarterly results, rapid weight-loss product expansion, and a strategic Novo Nordisk partnership. Despite trading at a high valuation, technical indicators suggest continued short-term momentum, with potential for a pullback near February highs. The company's evolution from a telehealth startup to a health-tech giant showcases its strong growth, profitability, and expanding service offerings.
Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced its intention to offer, subject to market and other conditions, $450 million aggregate principal amount of convertible senior notes due 2030 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Hims & Hers also expects to grant.
Hims & Hers Appoints AI Expert and Former President and CTO at Cruise as Chief Technology Officer
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Mo Elshenawy, a proven technology executive with deep expertise in artificial intelligence and large-scale infrastructure, as the company's new Chief Technology Officer. His appointment marks a key milestone as Hims & Hers accelerates its vision to build the next-generation healthcare platform, powered by AI and designed to deliver deeply pe.
Hims & Hers Health Shocks Investors With a Long-Term Forecast, but Is the Stock a Buy?
Following the company's first-quarter earnings report, shares of Hims & Hers Health (HIMS 5.21%) opened the following day considerably lower, only to sprint higher once trading began. This action is just one example of why the stock is a bit of a divisive name among investors.
Hims & Hers: 2030 Guidance Indicates Big Upside
Management's 2030 guidance includes $6.5 billion in revenue and $1.3 billion in adjusted EBITDA, focusing on personalized healthcare and geographic expansion. Anticipating management's guidance for 2025 and 2030, Hims & Hers could be undervalued by up to 62%. Apart from the guidance, the company needs to achieve growth rates in the mid-teens% to justify the current valuation.
Hims & Hers: Short Squeeze Or Strong Fundamentals? (Rating Downgrade)
Hims & Hers Health, Inc. Q1 results beat the Street's expectations, as I anticipated in February. The company reaffirmed FY 2025 guidance and increased the EBITDA range for the year. That said, I believe the rally on May 6 was driven by the high short interest and not by fundamentals. The availability of Eli Lilly and Novo Nordisk weight loss drugs on the Hims platform is significant, but the easing of drug shortages could affect Q2 subscriber numbers.
Hims & Hers Health: Healthcare Disruptor Building A Durable Moat (Initiate With Buy)
Hims & Hers Health reported strong Q1 '25 earnings, with 111% YoY sales growth and 38% subscriber growth. The company boasts over a 70% gross margin, 90% recurring revenue, and a compelling flywheel effect driven by machine learning and big data analytics. Risks include the untested business model, potential legal issues, and the complexity of international expansion, but the growth potential presented far outweighs these concerns.
Hims & Hers Jumps 18.2% on Incredible 111% Revenue Growth
Hims & Hers (HIMS 19.03%) stock soared 18.2% in trading on Tuesday after the company reported first-quarter revenue growth of 111% and an increase in 2025 guidance. The results were phenomenal and a short squeeze likely helped, which Travis Hoium discusses in this video.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for HIMS.